|
US2009214593A1
|
|
Immunogen platform
|
|
EP2185195A2
|
|
Immunogen platform
|
|
US2009092631A1
|
|
Glycosylated specificity exchangers that induce an antibody dependent cellular cytotoxicity (adcc) response
|
|
AU2007203138A1
|
|
Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
|
|
WO2008004992A2
|
|
Transdermal formulations containing hepatitis c virus immunogens and an ethoxylated oil
|
|
US2008295185A1
|
|
Transgenic mouse models of hepatitis C virus (HCV) and identification of HCV therapeutics
|
|
EP1799222A2
|
|
Compounds that inhibit replication of human immunodeficiency virus
|
|
US7335359B2
|
|
Glycosylated specificity exchangers
|
|
WO2004073703A1
|
|
Glycinamide derivative for inhibiting hiv replication
|
|
CN1777414A
|
|
Glycinamide derivative for inhibiting HIV replication
|
|
WO2004069873A2
|
|
Antigen/antibody or ligand/receptor glycosylated specificity exchangers
|
|
CA2506525A1
|
|
Hepatisis c virus nonstructural protein 4a (ns4a) is an enhancer element
|
|
US6933366B2
|
|
Specificity exchangers that redirect antibodies to bacterial adhesion receptors
|
|
US7022830B2
|
|
Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
|
|
WO03024995A1
|
|
Molecules that block viral infectivity and methods of use thereof
|
|
US6680059B2
|
|
Vaccines containing ribavirin and methods of use thereof
|
|
WO0224887A2
|
|
Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
|
|
US6455670B1
|
|
Pentamer peptide amide, ALGPG-NH2, that inhibits viral infectivity and methods of use thereof
|
|
US6593455B2
|
|
Tripeptide amides that block viral infectivity and methods of use thereof
|
|
RU2286172C2
|
|
Ribavirin-containing vaccines and methods for their application
|
